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Trichomonas vaginalis was originally considered a
commensal organism until the 1950s when the
understanding of its role as a sexually transmitted infection
(STI) began to evolve. Trichomoniasis has been associated
with vaginitis, cervicitis, urethritis, pelvic inflammatory
disease (PID), and adverse birth outcomes. Infection with T
vaginalis could have an important role in transmission and
acquisition of HIV. T vaginalis is site specific for the
genitourinary tract and has been isolated from virtually all
genitourinary structures. Asymptomatic disease is common
in both men and women, thus screening for disease is
important. Various sociodemographic factors have been
correlated with presence of T vaginalis, and may be used
to predict infection. Diagnosis is usually made from wet
mount microscopy and direct visualisation, which are
insensitive. DNA amplification techniques perform with
good sensitivity, but are not yet approved for diagnostic
purposes. In areas where diagnostic methods are limited,
management of trichomoniasis is usually as part of a
clinical syndrome; vaginal discharge for women and
urethral discharge for men. A single dose of metronidazole
is effective in the majority of cases. Outside of the United
States, other nitroimidazoles may be used and are as
effective as metronidazole. Metronidazole resistance is an
emerging problem, but its clinical importance is not yet
clear. Concomitant treatment of sexual partners is
recommended.
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T
richomoniasis is a sexually transmitted dis-
ease (STI) with important public health
ramifications; it has been associated with
vaginitis, cervicitis, urethritis, and pelvic inflam-
matory disease (PID). Trichomoniasis also
impacts upon birth outcomes and is a co-factor
in human immunodeficiency virus (HIV) trans-
mission and acquisition.1
Approximately 180 million women worldwide
may be infected with T vaginalis. Prevalence
estimates vary between populations studied,
but range from 5–74% in women and 5–29% in
men, with the highest rates reported in either sex
from STI clinics and in other high risk popula-
tions.2–5 In men, the prevalence is less well
described because many men are asymptomatic
and may not seek evaluation. Furthermore, the
diagnosis is less commonly sought in men.6 In
either sex, concomitant infection with other
sexually transmitted organisms occurs com-
monly.7 8 Because of the public health impor-
tance of this common STI, we review here the
clinical aspects of trichomoniasis.
METHODS
Using combinations of the keyword ‘‘trichomo-
niasis’’ with ‘‘epidemiology,’’ ‘‘diagnosis,’’ ‘‘man-
ifestations,’’ and ‘‘therapy,’’ a Medline search
was performed. The search was limited to
English language articles published in the pre-
vious 10 years. Editorials, letters to the editor,
case reports, and case series were excluded. The
resulting titles were searched for and limited to
‘‘trichomoniasis’’ or ‘‘Trichomonas vaginalis.’’
Resulting abstracts were reviewed and articles
were excluded if the focus was not clinically
relevant. Articles representing a developing body
of literature were limited to the most recent
publication date.
RESULTS
A total of 396 articles were retrieved through the
Medline search. Subsequent review by the
authors resulted in 195 articles with ‘‘trichomo-
niasis’’ or ‘‘T vaginalis’’ in the title. Abstracts
(n = 94) were reviewed; 52 of these were selected
and reviewed here.
Epidemiology
Among US women, race has been identified in
several studies as predictive of infection with T
vaginalis.9 This association is probably multi-
factorial, including access to care, personal
health practices, and socioeconomic factors.1
Older age, histories of previous STI, prostitution,
pregnancy, and drug use have also been asso-
ciated with trichomoniasis.10 11 The association
with older age is in contrast with the association
between age and other STIs, especially chlamy-
dia. Reproductive hormone levels may be partly
responsible for higher prevalence of trichomo-
niasis in older women.12 Among African women,
vaginitis including trichomonal vaginitis was
significantly associated with sexual debut at less
than 20 years, a partner who travelled fre-
quently, history of STI, and presence of abnormal
discharge.13 Concomitant STI diagnosis is com-
mon (15–28% chlamydial co-infection and 10%
gonorrhoeal co-infection rates) in women with
trichomoniasis, indicating the importance of
screening for other STIs.14 15
Among US men attending STI clinics, the
combination of age >30 years, discharge, and
diagnosis of non-gonococcal urethritis (NGU)
was predictive of infection with T vaginalis,
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although this finding was not supported in a separate
study.16 17 Sexual exposure to a woman with trichomoniasis
and history of trichomoniasis were also associated with
trichomoniasis in multivariate analyses.16 As in women,
concomitant infection with other urethral pathogens is
common in trichomoniasis. Mixed infections with T vaginalis
and Neisseria gonorrhoeae and/or Chlamydia trachomatis occurred
in seven of 980 rural Tanzanian men, while 61.5% of 91 men
with trichomoniasis in west Africa also had a gonococcal
infection.8 18 19
Finally, trichomoniasis facilitates spread of the HIV
epidemic. One theoretical calculation concludes that if
infection with T vaginalis increased the risk of HIV transmis-
sion by 90% in a population with 25% prevalence of
trichomoniasis, approximately 20% of cases of HIV would
be attributable to trichomoniasis.1 This relation could explain
some of the differences in rates of HIV infection in different
regions of Africa where rates of trichomoniasis and HIV seem
to be directly proportional.20
Clinical presentation
Women
T vaginalis is site specific for the genitourinary tract and has
been isolated from virtually all genitourinary structures.
However, many women diagnosed with trichomoniasis are
asymptomatic; in Zimbabwe 75% of women denied symp-
toms on direct questioning and 16% of these women had
trichomoniasis.13 When symptoms arise, the most common
presenting complaint among women diagnosed with T
vaginalis is vaginal discharge, seen in more than 50% of
cases, followed by pruritus or dysuria. One study of 200
Nigerian women demonstrated 74% with vaginal discharge
were infected with T vaginalis.2 On speculum examination,
the vaginal discharge may be of any colour or characteristic,
and although a frothy green discharge has classically been
associated with trichomoniasis, this was not observed in any
of 149 Nigerian women with discharge caused by trichomo-
niasis.2 The discharge may be malodorous with pH .4.5.7
Trichomoniasis has been associated with bacterial vaginosis
in other studies.21 22 Clue cells were found to be an
independent risk factor for trichomoniasis among 249
South African women attending family planning clinics.23
However, these characteristics are neither sensitive nor
specific. The clinician’s ability to predict vaginal infection
with T vaginalis based solely on physical examination was
shown to have a positive predictive value of 47% among
commercial sex workers in Cameroon.24
Cervical pathology can be commonly seen with trichomo-
niasis. Colpitis macularis, or ‘‘strawberry cervix,’’ (fig 1)
results from microscopic, punctate haemorrhages of the
cervix. T vaginalis is significantly associated with the clinical
finding of colpitis macularis. Cervical mucopurulence,
erythema, and friability have been observed.7 23 T vaginalis
may be associated with cervical cancer; however, confound-
ing factors, such as co-infection with HPV, have not been well
controlled for in some of these studies.25 Among HIV infected
women, T vaginalis infection was associated with PID.21
Trichomonal infections are neither restricted to nor
exclusive for the vagina, and urinary tract infection may be
common. Dysuria was observed in 29% of South African
women diagnosed with T vaginalis infection.23 Thus, con-
sideration should be given to the presence of trichomoniasis
for women with dysuria as a sole complaint.
Finally, there is some suggestion that women may harbour
T vaginalis for 3–5 years.26 The reasons for this are unclear, but
may include imperfect screening tools, genitourinary anat-
omy, or type of infecting strain.
Men
Less is known about T vaginalis infection in men. Current
estimates of asymptomatic infection in men vary. In one US
study, 23 of 50 patients with trichomoniasis were asympto-
matic.27 Among 23 east African men with trichomoniasis, 19
were asymptomatic.28 Finally, among 100 men presenting for
non-genitourinary complaints in the Central African
Republic, seven were diagnosed with trichomoniasis.8 When
symptoms of trichomoniasis become manifest, discharge may
be less profuse and purulent than that seen with gonococcal
infection.27 Men may also complain of dysuria. Of 103
Tanzanian men with trichomoniasis, dysuria occurred in
42%; only five men complained of urethral discharge.19
Finally, trichomoniasis was diagnosed in 66 of 410 men
from the Central African Republic with urethral discharge.8
In men, urethral discharge and dysuria are the most common
symptoms; however, some men diagnosed with trichomo-
niasis are asymptomatic.29 Many men clear T vaginalis from
the genitourinary tract within 2 weeks.30 Involvement of
other male genitourinary structures has been described, but
will not be reviewed here.
Diagnosis
Specimens
Suitable clinical specimens include urine, vaginal fluid,
semen, and endocervical smear. Because of discordantly
infected anatomical sites among men, testing from multiple
sites is advisable.31 Vaginal specimens for culture may be
either self collected with a swab, or collected by the clinician
with a swab or plastic loop.32 Self collected vaginal specimens,
which may have greater acceptability with patients, perform
similarly to clinician acquired specimens for the diagnosis of
trichomoniasis.33
Direct visualisation
These methods depend on identification of the organism on
microscopic examination of clinical specimens. Wet mount
preparation and culture rely on visual detection of sufficient
numbers of viable organisms with characteristic motility. Wet
mount preparation has been the most commonly used
method for diagnosis of trichomoniasis in women. Vaginal
secretions are obtained from the lateral walls and fornices
using a swab or plastic loop; in men, any urethral discharge,
prostate secretions, or urethral scrapings may be used. The
secretions are then suspended in 0.85% normal saline and
examined under the microscope. Because the organism will
quickly lose its characteristic tumbling motility, the specimen
should be examined as quickly as possible after it has been
obtained.34 Although this method has imperfect sensitivity, it
is both inexpensive and rapidly performed.35
Culture has long been considered the gold standard for
diagnosing T vaginalis infection. Several different media are
available for culture, including self contained systems. OfFigure 1 Colpitis macularis, or ‘‘strawberry cervix.’’ (Courtesy, CDC.)
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these media, Diamond’s modified has been shown to be
superior although the self contained system has been shown
to have equivalent performance.36 Culture is more sensitive
than wet mount preparation, because of the lower minimum
concentration of organisms required for a positive result.36
The drawbacks to culture include greater cost and prolonged
time to diagnosis (3–7 days). Screening with culture,
although far more sensitive than wet mount preparation,
may not be feasible; however, delayed inoculation after a
negative wet mount preparation could increase detection in
high prevalence populations without substantially increasing
cost.37
As a screening tool for trichomoniasis, Papanicolaou (Pap)
smear performs with low sensitivity (61%).38 In one study,
endocervical smears were less sensitive than ectocervical
smears, leading the authors to suggest that the ectocervical
smear may have greater utility for detecting T vaginalis on Pap
smear.39 Depending on the prevalence of T vaginalis in a
population, almost one third of women with Pap smears
positive for trichomoniasis receive unnecessary therapy.40 In a
meta-analysis of the performance of Pap smear compared to
wet mount preparation for the diagnosis of vaginal tricho-
moniasis, a three tiered approach for the interpretation of a
positive Pap smear was proposed.41 In high prevalence
populations (.20%), a positive Pap smear had a positive
predictive value (PPV) of 83%, whereas in lower prevalence
populations the PPV decreased. Confirmatory culture for T
vaginalis has been recommended for suspicious Pap smears in
low prevalence populations.41
Other staining and molecular probe methods have been
employed with direct clinical specimens.42 43 While rapidly
performed and having sensitivity similar to that of wet
mount preparation, they require access to specialised equip-
ment, skilled laboratory personnel, and sufficient financial
resources.
Nucleic acid amplification
Because of the insensitivity of wet mount preparation and the
problems with culture methods, nucleic acid amplification
methods, such as polymerase chain reaction (PCR), have
become increasingly attractive for diagnosing infection with T
vaginalis. PCR has the advantage of requiring only DNA, from
either viable or non-viable organisms, and in concentrations
as low as one organism per PCR reaction.44
PCR has been performed on several different types of
clinical specimens, most notably vaginal fluid and urine. Self
administered vaginal swabs have been used for PCR assays,
and performed at least as well as wet mount preparation,
although specificity is less than that of wet mount or
culture.45 Urine based PCR detection of T vaginalis has
performed with sensitivity and specificity of 64–90.8% and
93.4–100% in US women and 92.7% and 88.6% in African
men, respectively.46 47 This technology is not yet commercially
available.
Syndromic management
Screening for trichomoniasis may be problematic in resource
challenged settings. In such settings, the World Health
Organization (WHO) has promoted syndromic approaches
for managing STIs. However, using mathematical modelling,
Bowden et al demonstrated that syndromic management had
minimal effect on endemic prevalence, and that screening
was the most efficient method of control.26 In general,
syndromic management has been shown to work well for
genital ulcer disease for either sex, and urethral discharge for
men. The urethral discharge algorithm does not consider
trichomoniasis until after the patient has been treated for
gonorrhoea and chlamydia. Based on the prevalence of
trichomoniasis as a cause of urethritis, some experts
have suggested the addition of metronidazole or another
nitroimidazole to the initial therapy in the syndromic
management algorithm for urethral discharge.19 Syndromic
management of vaginal discharge performs poorly for women
because cervical discharge is a confounding factor. In a study
of 249 South African women attending antenatal clinics, only
one in three women treated for trichomoniasis based on a
risk score would actually have been correctly diagnosed with
trichomoniasis based on wet mount microscopy; overtreat-
ment using syndromic management compared to microbio-
logical diagnosis of trichomoniasis was observed in another
study.23 48
Treatment
Definitive therapy for trichomoniasis became possible with
the introduction of nitroimidazoles (metronidazole, tinida-
zole, ornidazole, carnidazole, and nimorazole). In a meta-
analysis of nitroimidazoles where the majority of studies used
tinidazole or metronidazole for treatment of trichomoniasis,
in short or prolonged courses of oral therapy, parasitological
cure resulted in 90% of cases.49 Topical metronidazole is not
effective for therapy for trichomoniasis.50 The Centers for
Disease Control and Prevention (CDC) has estimated that 5%
of clinical isolates of T vaginalis exhibited some degree of
metronidazole resistance.51 Metronidazole resistance may
predict tinidazole resistance; however, it is unclear if this
situation is true for the entire class of nitroimidazoles.52 The
CDC has proposed an escalated therapeutic regimen for
management of infection with resistant strains (fig 2).
Furazolidone, a nitrofuran, was shown to be effective in
vitro against both laboratory and clinical specimens with
high level metronidazole resistance, and topical paromomycin




was effective in seven of 12 patients infected with resistant
strains; however, paromomycin had adverse dermatological
effects.52 53 Alternatives for treatment of highly resistant
trichomoniasis exist but have not been subjected to the
rigours of clinical trials.
Side effects of nitroimidazoles include a bitter metallic
taste, nausea, and vomiting, a disulfiram-like reaction with
ingestion of alcohol and some central nervous system effects.
Despite the low doses required for treatment of trichomo-
niasis, side effects occur in more than half of patients,
especially with the metronidazole 2 g dose.49
Other management issues
Treatment relapse usually represents re-infection by an
untreated partner in the majority of cases, although newly
recognised chronic or drug-resistant infections are possible.9
Re-infection is common, occurring in 36% of subjects in one
study.11 Recommendations for concomitant treatment of the
male partner have been made since the 1960s and are now
the standard of care.54
Risk factors for re-infection with T vaginalis in HIV infected
women have been evaluated. In a study of 411 HIV positive
women, 36% were re-infected at least once with T vaginalis
over a mean follow up of 3.5 years. Predictors of re-infection
or recurrent infection in these women were age >22 years
and history of previous STI in multivariate analysis.11
Some pregnant women with trichomoniasis may present
with premature rupture of membranes, preterm labour.55
However, a randomised placebo controlled trial of 615
asymptomatic pregnant women with trichomoniasis did not
demonstrate a difference in rates of preterm birth between
the treatment and placebo groups.56 Although the reasons for
this finding are unclear, the authors speculated that
inflammatory responses to dying organisms or release of a
pathogenic virus might be responsible. Because of the
possible association with adverse birth outcomes, some
authorities recommend treating trichomoniasis in pregnant
women.54 The use of metronidazole in pregnancy has been
controversial because of its potential mutagenic and carcino-
genic potential. Increased risks of birth defects or teratogeni-
city have not documented.57 For clinicians concerned about
the possibility of effects on the fetus, intravaginal therapy
with metronidazole or clotrimazole could be considered as
alternatives; however, studies of these therapies have
demonstrated low parasitological cure rates.50 58
SUMMARY
T vaginalis infection is highly prevalent in sexually active
populations. Trichomoniasis is clearly associated with sig-
nificant public health problems, including HIV transmission.
Disease presentation is variable and diagnosis can be difficult
with the most commonly used methods. Certain socio-
demographic and behavioural risk factors may assist in
predicting infection. Treatment of trichomoniasis with one
dose of metronidazole is highly effective, and should be
delivered in conjunction with concomitant treatment of
sexual partners.
A majority of women and a significant proportion of men
with trichomoniasis are without any symptoms; these
patients would thus escape detection and treatment under
syndromic management recommendations. Control pro-
grammes must work towards increased screening in order
to have any effect on the burden of STIs.
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